Every 13F-reported equity position this quarter with its quarter-over-quarter change; each row traces to the filer's 13F-HR on EDGAR.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR
Every 13F-reported equity position this quarter with its quarter-over-quarter change; each row traces to the filer's 13F-HR on EDGAR.
ATP Life Science Ventures, L.P. (CIK 1593440) reported $898.3M across 3 reported positions in its SEC 13F filing for 2021-03-31. Largest positions: STOK ($666.6M, 74.20%), AKRO ($169.1M, 18.83%), KDNY ($62.6M, 6.97%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | STOK | Stoke Therapeutics, Inc. | $666.6M | 74.20% | 17.2M | Hold |
| 2 | AKRO | Akero Therapeutics, Inc. | $169.1M | 18.83% | 5.8M | Hold |
| 3 | KDNY | Chinook Therapeutics, Inc. | $62.6M | 6.97% | 4.0M | Hold |
Source: SEC Form 13F filings · as of 2021-03-31